Quantcast

Latest Bacillus anthracis Stories

2010-08-04 09:00:00

PINE BROOK, N.J., Aug. 4 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to...

2010-07-15 07:00:00

ANNAPOLIS, Md., July 15 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a New Zealand White Rabbit study showing that its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine was more immunogenic than a liquid formulation of rPA vaccine and produced a robust response with only 2 doses. The data were presented in a poster presentation...

ac6c5fb309fe6961f2be5a668298501c1
2010-06-23 10:56:05

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry. In the article, Dimitrios Bouzianas notes that several existing antibiotics are...

2010-05-19 09:59:12

Army scientists have discovered a way to "trick" the bacterium that causes anthrax into shedding its protective covering, making it easier for the body's immune system to mount a defense. The study, which appears in this month's issue of the journal MICROBIOLOGY, could lead to new approaches for treating anthrax infection. Bacillus anthracis, the causative agent of anthrax, is particularly lethal because of its protective coating, or capsule, which enables the pathogen to escape destruction...

37b211af10466eff781870cb2bfaa231
2010-05-02 08:31:20

Anthrax-causing bacteria can be engineered to shed their invisibility cloaks, making it easier for the immune system to eradicate it, according to a new study published in Microbiology. The work could lead to new measures to treat anthrax infection in the event of a biological warfare attack. Bacillus anthracis is a particularly lethal pathogen because it manages to escape recognition by the host's immune system by coating itself with a protective capsule around its surface. A key bacterial...

2010-02-24 07:00:00

ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new data from the Company's Valortim® anthrax anti-toxin program were presented at the 8th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Baltimore, Maryland, February 21-24, 2010. The data were presented by Dr. Alan S. Cross, Professor of...

5888cf903bf8043a13db8ab0492d62f7
2010-02-06 07:25:00

Health officials from Britain issued drug users an alert on Friday after a heroin user tested positive for the deadly anthrax infection, according to Reuters. It was the first such anthrax case seen in England caused by laced heroin. Nine people have died in Scotland and one in Germany during the past two months from the contaminated drug. Officials from the Health Protection Agency, in a statement, said the laced drug could be circulating through Europe now. It was believed last month that...

2009-12-04 12:30:00

ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is presenting results of a study demonstrating the effectiveness of Valortim® in an inhalation anthrax model in the New Zealand White (NZW) rabbit. The data are being presented during an oral session at the HHS Public Health Emergency Medical Countermeasures...

2009-12-04 10:01:00

ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C. The data were presented by...

2009-09-08 11:15:58

Scientists discover a gene in anthrax-causing bacteria may help defend against this form of bio-warfare. Spread of the deadly disease anthrax by spores of the bacterium Bacillus anthracis is a known terrorism risk and protection includes finding ways to treat the disease, according to an academic paper reviewed by Faculty of 1000. Scientists from the University of California (San Diego) have identified a gene in B. anthracis that not only contributes to the severity of the anthrax disease but...


Latest Bacillus anthracis Reference Libraries

11_ca5cd45b16f3d4936fde0520fef6557b
2011-04-14 14:43:25

Bacillus anthracis is a Gram-positive spore-forming, rod-shaped bacterium, with a width of 1-1.2µm and a length of 3-5µm. It can grow in aerobic or anaerobic conditions. It is the only known bacterium to synthesize a protein capsule and the only pathogenic bacterium to carry its own adenylyl cyclase virulence factor. They form oval spores located centrally in a non-swollen sporangium. These spores are highly resilient and can survive extreme temperatures, low-nutrient environments, and...

More Articles (1 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.